Showing posts with label Breakthrough. Show all posts
Showing posts with label Breakthrough. Show all posts

Wednesday, 29 March 2017

CBD Cannabidiol Oil A Major Breakthrough In The Struggle Against Nerve Pain


Today's post from peoplespharmacy.com (see link below) illustrates just how far we've come in finding solutions for neuropathic pain. Who would have thought ten years ago that marijuana and its derivatives would be able to play a major role in reducing severe pain (and...just as important, be sanctioned by the authorities because it helps in the current and over-hyped: 'war on opioids'). I can actually speak from personal experience regarding cannabis oil (CBD oil). I never expected it and was roundly skeptical but after a few days of 2 drops under the tongue, twice a day, my symptoms also reduced significantly. Now here I need to add a disclaimer:- my experience and the experience of those mentioned in the article, have absolutely no bearing on how you may react. As you probably know, neuropathy is a disease that is peculiar to each individual and each individual reacts differently to different treatments. Why do you think doctors are scratching their heads in frustration at not being able to provide a 'cure' or often, even help with the symptoms. There are over 100 sorts of nerve damage and over 100 causes - add that to over 100 potential treatments and you have one of the most frustrating and serious diseases on earth. This blog is aimed at providing information about as many options as possible but you still need to seek advice from your doctors and do your own research. An article such as this one below, needs to be looked at objectively and not jumped upon as being the 'elixir of life'. But you know all this don't you!

Cannabidiol Oil Solved Severe Seizure Problem and Painful Neuropathy Joe Graedon December 5, 2016 Diabetic Neuropathy (nerve pain)
 
Medical marijuana is now legal in many states but many people are unaware of the pros and cons. Does cannabidiol oil work for hard-to-treat pain and epilepsy?

Many doctors are skeptical about the benefits of medical marijuana. That’s because they did not learn about this “herb” in medical school. If it was discussed at all, the likelihood is that the lecture would have been part of a class on drugs of abuse rather than therapeutic benefits. Sadly, there has been relatively little research on medical marijuana. This reader shares a poignant story about cannabidiol oil.

Q. My 19-year-old son had intractable seizures starting at age 12. At age 17, he was up to 9 seizures a day despite taking three different meds (29 pills a day). The side effects were awful; he got so skinny that the doctors considered inserting a feeding tube.

Two years ago, I started him on cannabidiol oil (CBD). In California, you go to a special doctor who asks lots of questions to decide if you’d benefit from it. You get a special card for a dispensary.

We had to experiment to see how much he needed. We were able to gradually decrease his pills.

His neurologist was horrified at the idea two years ago, but he has watched in amazement as my son reduced his medication without a single seizure. CBD has made a world of difference in my son’s life!

A. Many states have approved the medical use of marijuana compounds. Cannabidiol oil does not cause the high associated with marijuana. Research is beginning to show benefit for some people with hard-to-treat epilepsy (Pharmacological Research, May, 2016).

A study in the journal Frontiers in Pharmacology (Sept. 30, 2016) also reported improvement:

“Novel antiepileptic compounds with new mechanisms of action, fewer side effects, and better safety and tolerability profiles have been approved over the last years. However, although more than 20 different drugs approved for the treatment of epilepsy exist today, around 30% of patients continue to have seizures…

“The medicinal effects of cannabis in epilepsy have been known for centuries and, nowadays, the anticonvulsant properties of its components have received increasing attention…

“The present report is in line with pre-clinical and preliminary clinical data suggesting that CBD may be effective for some patients with epilepsy.”

These researchers call for randomized controlled trials. We couldn’t agree more!


Stories from Readers About Cannabidiol Oil:
Ellie in Connecticut:

“Were it not for medical marijuana, I’d be taking opioids regularly to deal with my chronic pain. The world of med MJ is indeed a whole new world.

“Initially I stuck very closely to only oil based tincture strains that were very high CBD, with virtually no THC (the pyschoactive element in MJ that gets people high). Now I’m realizing that a small amount of THC along with high CBD produces the pain relief I’ve been looking for.

“Yes, I had to literally jump through hoops to become certified to purchase medical MJ in my state but it’s all been very worthwhile. Does the marijuana totally eliminate my pain? No, it doesn’t. But what it does is ease it back to a far more manageable level. I’m delighted to have this option to control my pain.”

David reports:

“My wife experiences relief from stroke related pain with oral CBD oil: an eye dropper full under the tongue when stomach is empty. She has experienced no adverse effects. It has a pleasant taste. CBD oil is derived from non-THC hemp and doesn’t get people high.”

Brian in California reports on cannabidiol for diabetic neuropathy:


“My diabetic neuropathy came on suddenly and without warning. The severity is such that I’ll literally scream out, even in a public place like a restaurant! The pain is very sharp but only lasts about a second. Sometimes it pulses. I’ve even been prescribed narcotics (opioids) but they don’t even touch it. Neurontin (gabapentin) doesn’t work, even after taking it for months.

“When I tried Marijuana it worked immediately and the relief lasted 3-4 days!

“Now, I make my own tincture and take about two dropperfuls every three days or so. If I forget, the pain will return to remind me, but if I have the tincture handy, it takes care of it immediately with NO side effects. I’m sure it is high in CBD but it also has some THC in it and I think a bit of THC is necessary for this purpose.

“I’m a retired Chiropractor with an additional degree in Natural Medicine. The synergy of the two substances working together is very important in natural products.”


A Doctor’s Perspective on Medical Marijuana:

If you would like to learn more about one physician’s experience with medical marijuana, we recommend our one-hour radio interview with David Casarett, MD, MA. In it you will learn about the use of cannabidiol oil and medical marijuana to treat neuropathic (nerve) pain. Dr. Casarett also explains how medical marijuana may be helpful in calming the agitation experienced by some patients with Alzheimer’s disease. Here is a link to the show.

https://www.peoplespharmacy.com/2016/12/05/cannabidiol-oil-solved-severe-seizure-problem-and-painful-neuropathy/

Friday, 22 July 2016

VM202 DPN A Breakthrough for Neuropathy


A new development in DNA medication for neuropathy is on the way. This article from 4-traders.com (see link below) tells that the Korean FDA has approved trials of VM202-DPN, which has shown extremely promising results in preliminary testing. Only two injections given over two weeks, produced long-lasting relief from pain. Approval from the American FDA is the bench mark generally for the rest of the world but it looks good so far. Hopefully by the time ViroMed get it on the market, it will have a more customer friendly name!

Approval from the Korea FDA for a Phase II clinical trial for diabetic peripheral neuropathy
04/13/2012 |

Its great potential has already been shown by the groundbreaking results from the Phase I/II clinical trial conducted in the US which confirmed the safety as well as the efficacy of VM202-DPN. Only two injections (at 2-week intervals) produced prolonging pain-reduction effects which were still lasting by the end of the 1-year follow-up period. ViroMed received approval for Phase II trial last year in the US based on these exciting and promising Phase I/II results. John A. Kessler, MD., of Northwestern Memorial Hospital, Chicago, US, will be the principal PI of this multinational Phase II study, and a total of 100 patients will be enrolled to evaluate the efficacy of VM202-DPN. About 7 hospitals in the US including Northwestern Memorial Hospital, Beth Israel Deacons Medical Center (Harvard Univ.), and the Mount Sinai Hospital, and 4-5 hospitals in Korea including Yonsei Univ. Severance Hospital will be participating for this study.

"This is an exceptional case among Korea's new drug development biotech companies." commented Jong-Mook Kim, the Director of Clinical Development Department of ViroMed. "Pre-existing drugs are only effective for temporary pain-relief and not without serious side-effects. With VM202-DPN's disease-modifying capabilities which would enable us to provide the fundamental cure for DPN patients, VM202-DPN will set a new trend in the current analgesic-driven diabetic neuropathy market."

According to the UK consulting firm Pelham Smithers Associates, the sales of existing medicines currently used to treat diabetic neuropathy were $1.5 billion in 2009. Since these drugs are symptomatic treatments which can only alleviate symptoms temporarily but cannot cure the underlying disease, it is expected that their market will not grow to over $2 billion. On the other hand, it is forecast that the global launching of disease-modifying drugs like VM202-DPN (estimated launching year: 2016) will drive the explosive growth of the market, expanding to be over $3 billion in 2020, and reaching $12 billion in 2025.
About VM202-DPN

VM202-DPN is ViroMed's proprietary DNA medicine using Hepatocyte Growth Factor (HGF), a gene that stimulates the growth of arteries. Recent experiments have shown that HGF also stimulates the growth and recreation of nerve cells, which raises exciting possibilities as a therapeutic for diabetic peripheral neuropathy. VM202-DPN has also been designed to have minimal side effects and to safely disappear from the body after its intended therapeutic effect has been produced.

Diabetic Peripheral Neuropathy market
There are approximately 285 million diabetes patients around the world, 50% of whom are also suffering from diabetic peripheral neuropathy (DPN) as a complication of diabetes. The number of DPN patients reaches 3.9 million in the US alone. (Diabetes Research and Clinical Practice, 2010)
According to Pelham Smithers Associates, an UK consulting firm specialized in data analysis, the sales of existing medicines currently used to treat diabetic neuropathy were $15 billion in 2009. After disease-modifying drugs like VM202-DPN are out to the global market (estimated launching year: 2016), it is forecast that the size of the market will be $2.5 billion in 2017, and grow to $5 billion in 2020.

Competitiveness of VM202-DPN
Existing drugs prescribed for the treatment of DPN are mostly pain killers, and the most-often-used of all is Pfizer's own "Lyrica" (worldwide sales of $1 bil/yr), a drug originally developed as epilepsy treatment. However, as "Lyrica" is the drug that temporarily relieves pain by blocking neurotransmitters, it must be used at twice-a-day basis for decades, and it is reported to produce nervous system-related side effects such as headache, insomnia and depression. Consequently, there have been high demands for safe and effective novel medicine for DPN as there are no fundamental treatments for it. To attend to those unmet needs, VM202-DPN is designed to treat the underlying disease by producing hepatocyte growth factor (HGF) that induces repair of damaged nerve cells and generation of micro-vessels in the affected regions of human body. Its great potential has already been shown by the resulting data from the Phase I/II clinical trial conducted in the US. It is reported that there were only 35% of the patients who experienced 50% or more reduction in pain level during clinical studies for "Lyrica"; however, 65% of the VM202-DPN treated patients experienced pain reduction only after two injections at 2-week intervals.

About ViroMed

ViroMed Co., Ltd. is a leading biotechnology company located in Seoul, Korea with a US presence in Atlanta and the San Francisco Bay Area. The company has two main areas of focus: DNA/protein-based biopharmaceuticals and phytotherapeutics (botanical drugs/nutraceuticals). ViroMed now has five main products in its pipeline targeting cardiovascular disease, cancer, and immune-related disorder, with clinical trials ongoing in the US, Korea, and China.www.viromed21.com.

http://www.4-traders.com/news/Approval-from-the-Korea-FDA-for-a-Phase-II-clinical-trial-for-diabetic-peripheral-neuropathy--14270738/